Elicio Therapeutics, Inc. 8-K

What Happened

• On June 24, 2026, Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K (Item 7.01) disclosing a virtual key opinion leader (KOL) event that highlighted the path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma.
• The event featured presentations by Zev Wainberg, M.D. (Professor of Medicine, UCLA; Co-Director, UCLA GI Oncology Program) and Peter Hosein, M.D. (Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami). The company presentation is furnished as Exhibit 99.1 to the report.

Key Details

• Filing date: June 24, 2026 (Form 8-K, Item 7.01, Regulation FD disclosure).
• Topic: path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma.
• Presenters: Zev Wainberg, M.D., and Peter Hosein, M.D.
• Exhibit: Presentation dated June 24, 2026 furnished as Exhibit 99.1 (Item 9.01(d)).

Why It Matters

• This disclosure gives investors public access to the company’s clinical and development messaging for ELI-002 7P and shows engagement with recognized oncology experts.
• While the filing does not include new clinical data or financial results, the presentation may provide insight into the company’s strategy, timelines or clinical priorities for its KRAS-targeted pancreatic program. The information was made public under Regulation FD via an 8-K filing.